Past exam of the behavioural neuroscience course of the year 2 of the psychology (experimental) course of the University of Oxford / 2022 / 2

Monoamine signalling contributes to mood regulation and to the actions of several antidepressants, but a universal “low transmitter causes depression” account is not established. Three propositions must be separated: a drug changes a molecular target; that change helps produce improvement; and the untreated disorder was caused by an opposite abnormality. Evidence for one proposition does not logically establish the next.

The monoamine hypothesis of depression developed from pharmacology. Monoamine oxidase inhibition reduces transmitter metabolism, while some tricyclic antidepressants inhibit transmitter reuptake; SSRI principally inhibit serotonin reuptake. Norepinephrine, serotonin and dopamine are distinct monoamines, acting through different receptors and pathways. The historical catecholamine proposal emphasized norepinephrine and already acknowledged the limitations of extrapolating from drug effects to disease mechanisms. Treating every low affective state as depletion of a single interchangeable brain substance is a substantially stronger claim.^[ref]

Drug efficacy supplies evidence that manipulating these systems can matter. A 2018 network meta-analysis synthesized 522 double-blind trials in adults with major depressive disorder and found each included antidepressant more efficacious than placebo on its response outcome. This is evidence synthesis, not a direct assay of patients' transmitter levels. Average effects, trial selection, publication bias, blinding and symptom-scale outcomes limit interpretation, and not every patient benefits. Even a perfectly demonstrated effect would show that an intervention can change a pathological state, not that it reverses its original cause. A downstream compensatory mechanism can be therapeutically useful without being the initiating lesion.^[ref]

Measuring the proposed deficiency is itself difficult. Peripheral serotonin is not a direct measurement of release at a particular central synapse. Metabolites combine synthesis, release, reuptake and degradation; receptor or transporter imaging is not simply a concentration gauge. A difference observed after illness onset might be causal, compensatory, treatment-related or associated with physiological stress. Establishing a general deficiency would require convergent measures in appropriate untreated populations, temporal precedence and a relationship to well-defined symptoms, not merely one group-average biomarker.

Precursor depletion supplies a more informative intervention. In a double-blind crossover study, patients in antidepressant-induced remission underwent acute tryptophan depletion and a control condition. Fourteen of 21 experienced a transient depressive relapse after depletion, whereas control testing did not produce significant behavioural effects. This supports dependence of some maintained remissions on serotonin precursor availability. It does not show that all untreated depressed patients began with low serotonin, that depletion is sufficient to generate the full syndrome in everyone, or that norepinephrine and dopamine are irrelevant. The selected, previously treated sample is central to the causal question actually tested.^[ref]

Time course also challenges a simple replenishment story. Initial transporter inhibition can occur before substantial clinical improvement. That discrepancy motivates slower receptor, circuit, learning and plasticity changes; it does not imply that early drug effects are absent. In a randomized placebo-controlled experiment, an acute dose of a norepinephrine reuptake inhibitor changed positive emotional processing in depressed participants before subjective mood or anxiety changed. Facial-expression judgments and emotionally valenced categorization and recall supplied behavioural readouts. These observations support an affective processing bias account: altered experience processing could accumulate into mood change. They do not establish that the measured early shift mediates every later clinical response.^[ref]

Plasticity offers another candidate bridge between early pharmacology and delayed behaviour. In mice, preventing antidepressant-associated adult hippocampal neurogenesis blocked behavioural effects in particular experimental assays. The evidence included genetic and localized irradiation approaches. It supplies a mechanistic dependency within that model, rather than merely a correlation between a drug and cell proliferation. However, the assays are not human major depressive disorder, the interventions can have additional effects, and necessity for one behavioural endpoint does not establish either sufficiency or a universal human mechanism.^[ref]

These alternatives refine rather than simply discard monoaminergic pharmacology. Serotonin or norepinephrine could regulate plasticity and learning within distributed neural circuits; baseline concentrations need not be uniformly low. Receptor sensitivity, pathway-specific activity and environmental experience could determine the effect of an intervention. Conversely, observing altered dopamine-related motivation would not prove that all anhedonia, cognitive slowing and sadness have one cause. Major depressive disorder groups multiple symptom patterns, so a mechanism associated with one dimension can be diluted or misleading when treated as a universal disease explanation.

The strongest conclusion available at the examination date is therefore conditional. Particular monoamine manipulations can alter affective processing and symptoms, and some treatment responses depend on monoaminergic function. The evidence does not identify a single brain-wide deficit that is necessary and sufficient for human depression. A useful successor account specifies transmitter, receptor, circuit, time scale and symptom, and tests how biological changes interact with learning and environment. This evaluation concerns explanatory evidence, not a recommendation to start, stop or choose a medication.